🐢 Weight loss drug is now the world’s top-selling medicine + 8 more stories
In the last 4 days ChatGPT read 120105 top news stories. After removing previously covered events, there are 9 articles with a significance score over 5.9. [6.2] Eli Lilly’s weight loss and diabetes drug becomes world’s best-selling medicine — statnews.com (+22) Eli Lilly’s diabetes and obesity drug, tirzepatide, has surpassed Merck’s cancer therapy Keytruda to […]
A preview of this year’s federal employee health benefits open season
Interview transcript: Jared Serbu All right, Tammy, the time is approaching very quickly here. November 10th is the start of Open Season. Not quite time for folks to be actually registering their decisions yet, but what should we be doing to prepare? Tammy Flanagan Yeah, it’s not too early to start looking at some things […]
STAT+: Novo Nordisk spent millions on weight loss searches that took people to its Ozempic website, analysis found
Novo Nordisk spent an estimated $7.5 million on 15,000 paid keywords related to weight loss searches, a new analysis found.
STAT+: Novo Nordisk spent millions on weight loss searches that took people to its Ozempic website, analysis found
Over a recent two-year period, Novo Nordisk spent an estimated $7.5 million on more than 15,000 paid keywords related to weight loss searches and generated more than 2.4 million visits to Ozempic.com, even though the medicine is not approved to combat obesity, a new analysis found. Notably, more than 3,500 keywords contained no mention of […]
Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark
George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.
American Heart Association: Thank Ozempic For Less Type 2 DIabetes
At the upcoming American Heart Association meeting, participants will learn of the epidemiological results of 63,656 military veterans with Type 2 diabetes in the Million Veteran Program who took GLP-1 receptor agonists (semaglutide – “Wegovy”, dulaglutide – “Trulicity”, etc.). The survey analysis found that those who also changed their lifestyle habits had a 50% lower […]
Reducing Early Stroke Recurrence Risk—Beyond Antithrombotics
About one-third of persons with ischemic strokes have diabetes, and an additional one-third have insulin resistance. After an ischemic stroke, diabetes is associated with approximately 20% higher risk of mortality, rehospitalizations, and ischemic stroke recurrence. Diabetes often occurs in the context of metabolic syndrome, obesity, hypertension, and dyslipidemia, which further compounds risk of downstream major […]
Viking Therapeutics Could Be Pharma’s Next Big Buyout Target
Quick Read GLP-1 market growth is fueling Viking Therapeutics‘ (VKTX) momentum with VK2735 in Phase 3 and VK2809’s NASH success. Viking is advancing dual therapies amid a $150 billion obesity opportunity. With a recent big buyout offer for a rival not as far along as Viking, the biotech could draw a big pharma bid next. […]
AI’s Power Problem
In this podcast, Motley Fool analysts Nick Sciple, Seth Jayson, and Tim Beyers: Discuss the vast sums being invested in power infrastructure, and whether current plans will be enough to meet demand. Cover the opportunities and complications from filling the void with existing and emerging nuclear technology. Play a nuclear-themed game of Faker or Breaker. […]
GLP-1 RA May Cut Surgery Risk in Patients With IBD
Use of GLP-1 RA in patients with IBD and obesity and/or T2D is significantly associated with weight loss and a reduced risk for surgery. Medscape Medical News